U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. MEDICAMAT S.A. - Clsoe Out Letter 8/19/14
  1. Warning Letters

MEDICAMAT S.A. - Clsoe Out Letter 8/19/14

  

Department of Health and Human Services' logoDepartment of Health and Human Services

 
 Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

 

AUG 19, 2014


Jean-Pierre Devidal
President
MEDICAMAT S.A.
59, Avenue Augustin-Dumont
92240 Malakoff, France


Dear Mr. Devidal:

The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter [CMS391311] dated April 19, 2013. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

 

Sincerely yours,

/S/

Steven D. Silverman
Director
Office of Compliance
Center for Devices and
Radiological Health

 

cc:
US Agent:
Lewis Ward
L.W. Ward & Associates, Inc.
4655 Kirkwood Court
Boulder, Colorado 80301

Back to Top